安捷伦科技宣布，其PD-L1 IHC 22C3 pharmDx检测试剂已获得美国食品药品监督管理局（FDA）的批准，可用于食管癌或胃食管结合部（GEJ）癌的伴随诊断。这一重要监管里程碑将为相关癌症患者的精准治疗提供关键依据。
安捷伦科技宣布，其PD-L1 IHC 22C3 pharmDx检测试剂已获得美国食品药品监督管理局（FDA）的批准，可用于食管癌或胃食管结合部（GEJ）癌的伴随诊断。这一重要监管里程碑将为相关癌症患者的精准治疗提供关键依据。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.